Arrowhead Reports the First Patient Dosing of Fazirsiran in the P-III Trial (REDWOOD) for Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Shots:
- The first patient has been dosed in the P-III trial (REDWOOD) evaluating fazirsiran (TAK-999/ARO-AAT) in a ratio (1:1) in 160 adult patients with AATD-LD
- The 1EPs of the study is a decrease from the baseline of 1 stage of histologic fibrosis METAVIR staging in the centrally read liver biopsy done @106wk. in patients with METAVIR stage F2 and F3 fibrosis
- Arrowhead & Takeda collaborated in Oct 2020 to co-develop fazirsiran & will co-commercialized in the US if approved under a 50/50 profit-sharing structure while Takeda will give Arrowhead ~$40M milestones as soon as this crucial study begins. Fazirsiran received BTD from the US FDA in July 2021 & ODD in Feb 2018 for AATD-LD
Ref: Arrowhead Pharmaceuticals, Inc. | Image: Arrowhead Pharmaceuticals, Inc.
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
